Ibrutinib, an irreversible inhibitor of Bruton tyrosine kinase (BTK) has shown profound benefits in high-risk CLL patients, with durable response rates and prolonged PFS and OS in a R/R CLL setting however, the majority of responses are partial. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.